Hawthorn executes deal with university

MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.

Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.

“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.

“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”